Median overall survival (OS) from THIO treatment extends to 16.9 months Newest data strengthens regulatory strategy CHICAGO / Feb 04, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company...Read more
New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif., Feb. 4, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist...Read more
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved enrollment of infants into the double-blind portion of the study sunRIZE...Read more
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo...Read more
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF...Read more
First-ever human clinical trial of a xeno-organ intended to allow for potential registration through the submission of a Biologics License Application to the U.S. FDA First xenotransplant is expected to occur around mid-year 2025 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 03,...Read more
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regeneron Pharmaceuticals | 30.20 4.53 | $697.05 |
| Eli Lilly | 15.64 1.93 | $826.07 |
| Abbott | 14.09 12.25 | $129.08 |
| Vertex Pharmaceuticals | 11.91 2.53 | $482.28 |
| Agilent Technologies | 10.94 8.04 | $147.04 |
| AbbVie | 10.75 6.00 | $189.95 |
| Finch Therapeutics | 9.70 538.89 | $11.50 |
| Axsome Therapeutics | 5.49 5.11 | $112.92 |
| Inspire Medical Systems | 5.44 2.83 | $197.38 |
| MiNK Therapeutics | 4.54 57.76 | $12.40 |
| Monopar Therapeutics | 4.45 10.22 | $48.00 |
| Medpace | 3.60 1.05 | $346.98 |
| Masimo | 3.56 2.07 | $175.70 |
| McKesson | 3.50 0.58 | $603.32 |
| Aligos Therapeutics | 3.46 15.33 | $26.03 |
| Quantum BioPharma | 3.43 107.86 | $6.61 |
| TransMedics | 3.38 4.92 | $72.14 |
| Praxis Precision Medicines | 3.23 4.02 | $83.49 |
| Company | Volume | Last Trade |
|---|---|---|
| Azitra | 244,660,071 | $0.28 |
| Tonix Pharmaceuticals | 136,515,560 | $0.15 |
| Invivyd | 95,799,437 | $1.25 |
| Quantum BioPharma | 76,297,742 | $6.61 |
| Pfizer | 66,715,583 | $25.87 |
| Evaxion Biotech | 62,603,160 | $3.23 |
| Quoin Pharmaceuticals | 48,592,225 | $0.31 |
| Merck | 46,210,502 | $90.60 |
| Kairos Pharma | 32,496,319 | $1.77 |
| MAIA Biotechnology | 24,939,741 | $2.00 |
| Walgreens Boots Alliance | 22,894,839 | $9.89 |
| Moderna | 22,597,293 | $34.17 |
| Senseonics | 19,635,360 | $0.94 |
| Calidi Biotherapeutics | 17,764,495 | $1.32 |
| Cumberland Pharmaceuticals | 16,258,254 | $3.60 |
| Teva Pharmaceutical | 15,570,757 | $17.06 |
| Tempus AI | 15,422,713 | $62.30 |
| Recursion | 15,177,765 | $7.61 |
| Mersana Therapeutics | 14,788,369 | $0.60 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
